Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Nerve Growth Factor × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

pembrolizumab 192 Nivolumab 108 Cyclophosphamide 105 Carboplatin 88 venetoclax 69 Gemcitabine 68 Bevacizumab 68 fludarabine 63 Dexamethasone 62 Specimen Handling 60 Injections 59 Magnetic Resonance Spectroscopy 57 Paclitaxel 56 atezolizumab 54 Biopsy 54 Cisplatin 47 Ipilimumab 46 Temozolomide 42 Rituximab 42 Pemetrexed 41 Docetaxel 39 Azacitidine 39 Oxaliplatin 38 Radiotherapy 37 Lenalidomide 35 Fluorouracil 35 Cetuximab 35 Prednisone 34 Irinotecan 33 Cytarabine 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07008703 2025-06-06

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1/2 Recruiting

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡